Compare CMRE & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMRE | XNCR |
|---|---|---|
| Founded | 1974 | 1997 |
| Country | Monaco | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2010 | 2013 |
| Metric | CMRE | XNCR |
|---|---|---|
| Price | $15.37 | $27.91 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $12.00 | ★ $22.33 |
| AVG Volume (30 Days) | 324.0K | ★ 1.3M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.80 |
| P/E Ratio | $5.55 | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $10.84 | $7.91 |
| 52 Week High | $18.06 | $30.61 |
| Indicator | CMRE | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 54.31 | 65.43 |
| Support Level | $15.16 | $11.20 |
| Resistance Level | $15.86 | $30.61 |
| Average True Range (ATR) | 0.44 | 1.54 |
| MACD | 0.06 | -0.09 |
| Stochastic Oscillator | 73.33 | 66.83 |
Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and others. The company provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.